Investigational drug · Phase 2
IOV-4001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IOV-4001"
First trial start
2022
Jul 20, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IOV-4001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable Melanoma
- Metastatic Melanoma
- Stage III Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IOV-4001" as an intervention, largest first.
Iovance Biotherapeutics, Inc.Industry
NCT05361174 · 53 participants (planned) · Start Jul 20, 2022 · Primary completion Sep 2027
Drug: IOV-4001 · For: Unresectable Melanoma; Metastatic Melanoma; Stage III Non-small Cell Lung Cancer and 1 more
Sites: Los Angeles, California; Miami, Florida; Orlando, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.
Zeng H, Mei W, Zeng C · Curr Treat Options Oncol 2026
Also in development for Unresectable Melanoma
- IO102-IO103Phase 33 trials
IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma
- ipilimumab and nivolumabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- LNS8801Phase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- nivolumab and relatlimabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- EVX-01Phase 21 trial
Evaxion Biotech A/S · Melanoma Stage IV, Unresectable Melanoma
- IOV-3001Phase 21 trial
Iovance Biotherapeutics, Inc. · Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.